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Abstract
Psychiatric disorders are among the most common human illnesses; still, the molecular and 
cellular mechanisms underlying their complex pathophysiology remain to be fully elucidated. 
Over the past 10 years, our group has been investigating the molecular abnormalities in major 
signaling pathways involved in psychiatric disorders. Recent evidences obtained by the Instituto 
Nacional de Ciência e Tecnologia de Medicina Molecular (National Institute of Science and 
Technology – Molecular Medicine, INCT-MM) and others using behavioral analysis of animal models 
provided valuable insights into the underlying molecular alterations responsible for many complex 
neuropsychiatric disorders, suggesting that “defects” in critical intracellular signaling pathways 
have an important role in regulating neurodevelopment, as well as in pathophysiology and 
treatment efficacy. Resources from the INCT have allowed us to start doing research in the field 
of molecular imaging. Molecular imaging is a research discipline that visualizes, characterizes, and 
quantifies the biologic processes taking place at cellular and molecular levels in humans and other 
living systems through the results of image within the reality of the physiological environment. 
In order to recognize targets, molecular imaging applies specific instruments (e.g., PET) that 
enable visualization and quantification in space and in real-time of signals from molecular imaging 
agents. The objective of molecular medicine is to individualize treatment and improve patient 
care. Thus, molecular imaging is an additional tool to achieve our ultimate goal.
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Medicina molecular: um passo em direção à medicina personalizada
Resumo
Os transtornos psiquiátricos estão entre as doenças humanas mais comuns. Os mecanismos celulares 
e moleculares subjacentes à sua complexa fisiopatologia ainda não estão totalmente esclarecidos. 
Nosso grupo está envolvido na investigação de anormalidades moleculares nas principais vias de 
sinalização das doenças psiquiátricas nos últimos 10 anos. Evidências recentemente obtidas pelo 
Instituto Nacional de Ciência e Tecnologia de Medicina Molecular (INCT-MM), utilizando análise 
comportamental de modelos animais, forneceram informações valiosas sobre as alterações 
moleculares subjacentes responsáveis por muitos distúrbios neuropsiquiátricos complexos, 
sugerindo que os “defeitos” nas vias de sinalização intracelular têm um papel importante na 
regulação do neurodesenvolvimento, bem como na fisiopatologia e eficácia do tratamento. 
Recursos do INCT nos permitiram iniciar pesquisas na área de imagem molecular. A imagem 
molecular é uma disciplina de investigação que visualiza, caracteriza e quantifica processos 
biológicos que ocorrem em níveis celular e molecular em seres humanos, e em outros sistemas 
vivos, através dos resultados de imagem dentro da realidade do ambiente fisiológico. A fim de 
reconhecer alvos, a imagem molecular aplica instrumentos específicos (PET, por exemplo) que 
permitem a visualização e quantificação em espaço e tempo real dos sinais dos agentes de 
imagem molecular, fornecendo medições de processos a nível molecular e celular. O objetivo da 
medicina molecular é individualizar o tratamento e melhorar a assistência ao paciente. Desse 
modo, a imagem molecular consiste em mais uma ferramenta para atingirmos nosso objetivo final.
©2012 Elsevier Editora Ltda. Todos os direitos reservados.
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Introduction
Psychiatric disorders are among the most common and de-
structive human illnesses; still, the molecular and cellular 
mechanisms underlying their complex pathophysiology re-
main to be fully elucidated. Over the past 10 years, our group 
has been investigating the molecular abnormalities in the 
main signaling pathways of psychiatric disorders. In 2008, this 
group developed a project that was funded by the National 
Institute of Science and Technology - Molecular Medicine 
(INCT-MM). Recent evidences obtained by us and others using 
behavioral analysis of animal models are providing valuable 
insights into the underlying molecular alterations responsible 
for many complex neuropsychiatric disorders, suggesting that 
“defects” in critical intracellular signaling pathways have an 
important role in regulating normal neurodevelopment, as 
well as in pathophysiology and treatment efficacy. These evi-
dences are supported by the fact that the signaling pathway 
components are indirect targets of the most effective drugs 
for treating these disorders, such as antipsychotics, antide-
pressants, and mood stabilizers. Remarkably, the mechanisms 
by which these drugs exert their therapeutic actions are 
unknown, and the specific downstream effector molecule(s) 
that must be targeted for therapeutic efficacy remain to be 
determined, which is a crucial step for the development of 
novel and more effective medications to become possible. 
The surrogate in molecular medicine is to personalize the 
medicine for improving patient care.
These evidences have stimulated our interest in investi-
gating genetic animal models, behavior and molecular basis 
of eletroconvulsotherapy, neurodevelopment, neuroprotec-
tion, and neuroinflammation, among others. Therefore, 
the challenging role of discovering how molecular alterations 
in signaling pathways are associated with psychiatric symp-
toms, provided by this research, seems to be a promising and 
attractive tool for new therapeutic approaches with greater 
efficacy and fewer undesirable side-effects. 
Molecular medicine applied to psychiatry:  
animal models
Our group is composed by researches not only from the psy-
chiatry field but also from the basic research. To develop our 
objectives we work with many different tools and expertise 
that are briefly described bellow. 
Zebrafish
Zebrafish is a fish model for human diseases that is gaining 
increasing attention as a model for psychiatric disorders.1 
Several recent studies have used this model to study the neuro-
developmental basis of psychiatric disorders and the mechanisms 
involved in pharmacological treatment.2 There are three main 
advantages of using zebrafish as a model for psychiatric dis-
order studies. First, the brain anatomy is conserved among 
fish and humans, but the patterns of zebrafish neural circuitry 
are simplified. Second, the emergence of motor behavior 
occurs just few days after fertilization, which makes it pos-
sible to measure the behavioral effects of pharmacological 
treatment and genetic manipulations in early stages. Third, 
because the development is external, it is easy to control 
environmental factors and to perform molecular-genetic and 
pharmacological experiments.3,4
There are three research projects using zebrafish being 
developed by this group:
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The modulation of metabolism by neurotransmitters and 
the effects of antipsychotics on metabolic pathways
Dopamine and serotonin are neurotransmitters involved in 
fat metabolism regulation.5 Furthermore, a common side 
effect of atypical antipsychotic treatment is the metabolic 
syndrome.6,7 However, the mechanisms involved in this regu-
lation are still unknown. We use zebrafish as a model to 
investigate fat metabolism regulation by neurotransmitters. 
The main advantage of using zebrafish in these studies 
is that, over the first days after fertilization, the zebrafish 
larvae are nourished by the yolk sac. Thus, the larvae can 
survive for several days after hatching without being fed.8 
Therefore, it is possible to study the mechanisms involved in 
the metabolism without the intrusive variable of eating be-
havior. Our group is using genetic and pharmacological tools 
to study the neuronal receptors and intracellular pathways 
involved in metabolism. For this, the zebrafish larvae are 
chronically bath-treated with dopaminergic and serotonin-
ergic agonists and antagonists. Additionally, specific genes 
related to neurotransmitter signaling are knocked down by 
morpholinos. Afterwards, the larvae are incubated in Nile 
red, which dyes phospholipids, cholesterol, and triglycerides. 
By microscopy, these larvae are observed in both yellow and 
red wavelengths, to evaluate the levels of phospholipids, 
cholesterol, and triglycerides, respectively. Furthermore, to 
investigate the receptors and intracellular pathways involved 
in metabolism regulation, the brains of the zebrafish larvae 
are dissected, and gene expression and protein phosphoryla-
tion are evaluated by RT-PCR and western blot.
With this model, we may elucidate direct neurophysi-
ological functions in metabolism and the association of 
neuropsychiatric disorders and metabolic syndrome.
The neural circuitry and intracellular pathways involved 
in antipsychotic treatment and behavior
Dopaminergic receptors are the main target of antipsychot-
ics.9 However, studies of the mechanisms and location of 
antipsychotic effects are still needed. The complexity of the 
dynamics of neuronal receptors and neural circuitry poses 
a challenge for a full understanding of the systems involved 
in pharmacological treatment. Recently, many studies have 
shown that the neuroanatomical patterns of zebrafish lar-
vae are analogous to human neuroanatomy, but reasonably 
simplified, showing that zebrafish are a relatively simple 
integrative system for research in neuroscience.10,3 
Many studies have shown alterations in the intracellular 
pathways regulated by dopamine (such as, downregulation 
of DARPP-32 and Akt) in the frontal cortex of schizophren-
ics and bipolar disorder patients.11-13 It was demonstrated 
that dopamine modulates the activity of Akt in adult mice 
striatum.14 This Akt regulation modulates the motor behavior 
of mice.14 Several studies have demonstrated that the do-
paminergic machinery is expressed in the brain of zebrafish 
larvae as early as one day post-fertilization, and regulates 
larval motor behavior.2 Therefore, we investigated which 
dopaminergic receptors modulate the Akt intracellular 
pathway in the brains of zebrafish larvae, as well as their 
functions in larval motor behaviour. It was demonstrated 
that dopamine regulates the Akt activity in a similar way to that 
occurring in the mammalian brain.15 Dopamine specifically 
modulates the phosphorylation of Akt at threonine 308 in 
the telecenphalon of zebrafish larvae15. Furthermore, this 
modulation is through the dopaminergic receptor D2, which 
also modulates motor behavior through the regulation of Akt 
activity.15 On the other hand, the dopaminergic D1 receptor 
increases motor behavior.15 Afterwards, it was observed that 
both the decrease and increase of dopaminergic signalling can 
regulate the motor behavior of zebrafish larvae, suggesting 
an inverted-U shaped function of dopamine in the behavior, 
as it is postulated for attention deficit and hyperactivity 
disorder (ADHD).15
After the description of dopaminergic signalling and the 
different functions of diverse dopaminergic receptors in 
motor behavior, this group is studying the effects of both 
typical and atypical antipsychotics in intracellular pathways. 
It is likewise investigating the effects of antipsychotics on 
the larval motor behavior, as well as which neuronal circuits 
are involved. The use of zebrafish in this research will enable 
progress towards a holistic understanding of the mechanisms 
involved in antipsychotic treatment.
The role of neurotransmitters in brain development
Several studies have suggested that abnormalities during 
neurodevelopment could be involved in neuropsychiatric 
disorders.2 Imbalances of both dopamine and serotonin are 
associated with many neurodevelopmental disorders, such as 
schizophrenia, autism, and ADHD.2,16 Furthermore, dopami-
nergic and serotoninergic receptors are the main target of the 
pharmacological treatments for these diseases.9 Interestingly, 
both neurotransmitters modulate intracellular pathways 
involved in neurodevelopment (e.g., Akt).2,16 However, the 
role of both neurotransmitters in neurodevelopment still 
remains to be fully understood. 
On that ground, we have studied the role of different 
dopaminergic receptors in the development of the GABAergic 
system, which is altered in brains of schizophrenic and au-
tistic patients.17,18 We used the zebrafish model to do this, 
since its development is external, allowing for better control 
of environmental factors and pharmacological manipula-
tion. The zebrafish larvae were chronically bath-treated 
with dopaminergic agonists and antagonists in a specific 
developmental window (3 to 5 days post-fertilization). It was 
shown that dopamine modulates the number of GABAergic 
neurons through dopaminergic D2 receptor.15 The theoretical 
inverted-U shaped model for dopamine is also observed in 
the development of GABAergic system in the telencephalon 
of zebrafish larvae, suggesting a fine-tuned function of do-
pamine in neurodevelopment.15 Furthermore, a correlation 
was observed between alterations in motor behavior and 
changes in the GABAergic development caused by dopamine 
abnormalities.15 
Thus, we are using zebrafish as an integrative model to 
understand the developmental basis of psychiatric disorders, 
which in addition to the studies using other models, including 
humans, will facilitate translational research. 
Caenorhabditis elegans: a model for studying 
neuropsychiatric and metabolic disorders
Obesity has emerged as a major health problem implicated 
in several human diseases.19-21 Studies aimed at understand-
ing the physiological mechanisms of body weight regulation 
have revealed that the central nervous system (CNS) plays 
RBP -  02.indb   84 07/02/2012   15:57:46
85Molecular medicine: a path towards a personalized medicine
a critical role in energy homeostasis.22 The CNS integrates 
internal and external cues of energy demand and availabil-
ity to coordinate behavioral, physiological, and metabolic 
responses of an organism over time.22-24 However, the neural 
circuits and molecular mechanisms underlying the perception 
of and responses to different energetic states remain poorly 
understood. A number of findings point to the monoamines as 
central regulators of energy balance. For instance, antipsy-
chotics having monoamine receptors as their targets, which 
are used for treating schizophrenia, lead to major metabolic 
disturbances. Thus, while a range of data highlight a rela-
tionship involving mental disorders and energy balance, the 
precise molecular background remains unresolved. 
Caenorhabditis elegans provides a genetically tractable 
system for rapid and functional analysis of various fat and 
neuronal regulatory pathways in the context of an intact 
animal.25-28 As in mammals, C. elegans neural sensory mecha-
nisms gauge environmental conditions and coordinate myriad 
behavioral and physiological responses.29,30 Its conserved gene 
systems reveal many parallels with vertebrates and, together 
with a simple nervous system composed of 302 neurons, ap-
pears as an attractive model for study of neuronal control 
of metabolism.
Using vital dyes as Nile red and BODIPY-labeled fatty acids 
or biochemical approaches as thin-layer-chromatography and 
gas-chromatography/mass-spectrometry or label-free images, 
based on Raman scattering microscopy, it is possible to assess 
worm’s metabolic state as reflected in triglyceride content.
Following this strategy, our group investigated the effects 
of dopamine signaling on C. elegans fat content and found that 
increased dopamine signaling is associated with fat reduction 
(Figure 1). Analyses of dopaminergic receptors loss of function 
mutants revealed an intricate relationship that ultimately 
results in fat breakdown via fat oxidation pathways. 
The idea that dopamine may influence fat stores through 
modulation of cellular bioenergetics brings forth a new aspect 
of dopamine signaling to be explored. Indeed, treatment with 
a dopamine D2 receptor agonist has recently been found to 
increase resting energy expenditure in women.31,32
We aim to widen our data searching for the bioenergetic 
outcomes that follows concurrent manipulation of dopaminer-
gic and serotoninergic systems in C. elegans. Therefore, new 
roles for monoamine signaling in the regulation of peripheral 
metabolism may be found and assist in studies of humans.
Clinical and neuropsychological models
Many thematic clinical services have been organized to sup-
port clinical research: affective, schizophrenia, anxiety dis-
orders, obsessive-compulsive disorder, and children, elderly, 
and women mental health. These services are structured in 
order to allow a complete clinical and neuropsychological 
characterization, beyond psychiatric diagnosis, of the enrolled 
patients. As an example of this approach we can refer to 
suicidal behavior studies. It is well established that suicidal 
behavior runs within families and that this familial transmission 
is independent of the transmission of psychiatric disorders per 
se and linked to a serotonergic dysfunction. Taken together, 
these data show that a phenotypic stratification, taking into 
account the suicidal behavior history, is of pivotal importance 
when performing association studies between psychiatric 
disorders and genetics, particularly serotonin related genes. 
Interestingly, suicidal behavior is a complex phenotype itself, 
and a fully characterization of suicidal behavior is necessary 
because a gene may be associated with some types of suicidal 
behavior (e.g., impulsive or violent) but not with others. Using 
this approach, we found an association between a functional 
polymorphism of the serotonin transporter gene and violent 
suicide behavior, regardless of psychiatric diagnosis, but it 
was not associated with a psychiatric diagnosis itself,33,34 sug-
gesting that suicidal behavior could be a confounding factor 
when studying other serotonergic-related genes in the context 
of psychiatric disorders with high risk of suicidal behavior.
Development and use of neuropsychological 
assessment resources
Neuropsychological assessment is an important tool applied 
to the characterization of behavioral and cognitive functions 
related to brain development under normal and pathological 
conditions. The use of this clinical resource is important both 
for diagnostic and therapeutic interventions. The Laboratory 
of Neuropsychological Investigation (LIN) of INCT-MM aims to: 
a) adapt and develop neuropsychological tasks for use in 
research and clinical practices concerning developmental 
psychopathology issues across the life span; 
b) pursue neuropsychological and personality assessment 
for characterization of cognition and behavior aspects of 
neuropsychiatric diseases; 
c) contribute to studies concerning the relationship 
between molecular biology and cognitive phenotypes.
Development and adaptation of neuropsychological tasks
Due to the lack of neuropsychological tasks adapted to 
Brazilian subjects, several neuropsychological tests and 
Figure 1  A straightforward strategy for fat measurement in 
Caenorhabditis elegans.
(A – B) Animals exposed to dopamine have their fat content measured through 
fluorescence methods. (A) Illustration of strategy to uncover molecular 
machinery related to fat regulation by certain compound. (B) Dopamine 
exposure reduces fat stores as visualized by Nile red and BODIPY-labeled 
fatty acids.
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scales, which have been worldwide used in cognitive and 
personality assessments, were selected and submitted to 
psychometric studies. These tasks were selected and sub-
mitted to cross-cultural adaptation and studies concerning 
its psychometrics properties in Brazilian subjects.35 Tasks 
presenting appropriate psychometric properties are used for 
both research and clinical practices. 
Neuropsychological assessment of neuropsychiatric 
diseases
Cognitive and behavioral symptoms are core manifestations 
in neuropsychiatric diseases. Some of these characteristics 
are important for diagnostic proposes (e.g., cognitive decline 
in elderly people or in learning disabilities in childhood). One 
important research objective is to assess different cognitive 
domains in neuropsychiatric disorders in childhood and ado-
lescence (e.g., ADHD, Learning Disabilities, Infantile Bipolar 
Disorders, and Developmental Coordination Disorder), adult-
hood (e.g., Bipolar Disorders, Obsessive Compulsive Disorder, 
Schizophrenia, ADHD, and Anxiety), and elderly (e.g., Dementia, 
Pseudodementia, Mild Cognitive Impairment). In the Psychiatric 
Unit ambulatories of the Clinical Hospital at UFMG, patients are 
submitted to a comprehensive neuropsychological assessment 
which serves both for clinical and research proposes. The as-
sessment encompasses areas, such as intelligence, memory, 
attention, executive functions, personality, and motor behavior.
Neuropsychological assessment has been an important 
source of knowledge concerning frequent symptoms pre-
sented by subgroups of patients. Therefore, we are interested 
in the relationship between some clinical manifestations in 
psychiatric disorders and cognitive processes. For instance, 
we have studied in a sample of adults diagnosed with bi-
polar disorder (during an euthymic phase) the relationship 
between executive functions and suicide attempts,36 psy-
chotic symptoms and episodic memory,37 and anxiety and 
impulsive behavior. Another issue of interest is the neuro-
psychological predictors of success in pharmacological and 
non-pharmacological interventions. In this research field, we 
are conducting a study concerning the neuropsychological 
predictors of success in psychoeducation of bipolar patients 
and treatment adherence in schizophrenic patients.
Molecular basis of cognitive and behavioral symptoms in 
neuropsychiatric population
The main research focus of LIN-INCT in the next years will be 
related to the increase of studies concerning molecular basis of 
cognition and behavior. For this propose, the integration between 
neuropsychological assessment and molecular genetics is been 
used and we pretend to include the neuroimaging methods. 
An important research issue of LIN-INCT is the identifica-
tion of cognitive endophenotypes in psychiatric disorders. An 
endophenotype must meet certain criteria, such as associa-
tion with a genetic polymorphism, inheritance, and disease 
association parameters. In this line of research, LIN-INCT is 
collaborating in studies concerning the relationship between 
some genetic polymorphisms related to neurotransmission 
and specific cognitive manifestations. For instance, we have 
carried out studies on the relationship between the func-
tional polymorphism of 5-HTTLPR and impulsive behavior in 
obsessive compulsive disorder,38 bipolar disorder, and normal 
subjects.39 Regarding the polymorphism val66met of BDNF, 
we have studied its relationship with decision-making process 
in obsessive compulsive disorder40 and executive functions in 
bipolar disorder patients.41 Studies involving patients’ rela-
tives and normal health controls are in progress at the INCT 
of Molecular Medicine, and LIN-INCT is collaborating in these 
studies whose results will add information concerning cogni-
tive and behavioral endophenotypes in psychiatric diseases. 
Pharmachological assays and Models
Peptide toxins as drug prototypes and 
pharmacological tools
Another line of research developed by National Institute of 
Science and Technology – Molecular Medicine (INCT-MM) aims 
to reveal the pharmacological actions of some peptides, 
particularly the peptide toxins purified from the venom of 
the Brazilian spider Phoneutria nigriventer. Some of these 
toxins were proven to be useful for pain treatment, as well 
as for preventing neuronal death related to ischemic insults 
and cardiac arrhythmias. The proposed actions of these toxins 
in pain treatment and to prevent neuronal death were based in 
previous studies conducted by our group, which showed that 
these toxins are calcium channel blockers. Previously, we have 
shown that the venom also has a toxin (Tx3-1) that blocks 
A-type K+ currents and protects against cardiac arrhythmias.42
It has been shown that some fractions of the venom has 
an inhibitory action on voltage-gated calcium currents, on 
neurotransmitter release, and on synaptic vesicle exoci-
tosis.42 The spider-care facilities, venom extraction, and 
pharmacological fractions purification were based on previ-
ous work.43 This work is performed in collaboration with a 
governmental health foundation in Brazil called Fundação 
Ezequiel Dias (FUNED), however all the pharmacological 
assays are done at INCT-MM.
Phα1β (also known as Tx3-6) is one of the peptide toxins 
obtained from P. nigriventer venom. It has been shown that 
this toxin is capable of blocking N-type voltage-gated calcium 
channels. Subsequently, we demonstrated that Phα1β exerts 
antinociceptive action both in acute and in chronic pain in 
rat models.44 By comparison, Phα1β showed more long lasting 
antinociceptive effect than ω-conotoxin MVIIA. Furthermore, 
we have shown that Phα1β induces in rodents fewer side 
effects than ω-conotoxin MVIIA. ω-conotoxin MVIIA is the 
prototype for Ziconotide (Ellan Pharmaceuticals), which is 
the first toxin, calcium channel blocker, approved by the FDA 
for pain treatment in humans.
Phoneutria toxins Tx3-3 and Tx3-4 are potent blockers 
of voltage-gated calcium channels; however, different from 
Phα1β, they exert markedly inhibitory effect on P/Q-Type 
voltage-gated calcium channels. While tested in an in vitro 
model of ischemic injury, Tx3-3 and Tx3-4 were able to pre-
vent neuronal death in the hippocampal CA1 region,45 as well 
as in the retina.46 In both cases, the neuroprotective effect 
was related to inhibition of glutamate release by tissues, 
thus interrupting the neurotransmitter-mediated excitotoxic 
effect caused by the ischemic insult. 
Pain is a clinical symptom prevalent in ~20% of adults. 
Pain causes physical and emotional stress, in addition to being 
directly responsible for loss of workers’ productivity. The USA 
govern spends ~U$60 million annually treating pain, and the 
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International Association for the Study of Pain (IASP) estimates 
that half the people do not receive adequate pharmacological 
treatment. Not less important than a public health problem, 
stroke is now ranked as the second global cause of death. The 
reasons cited above are some of the driving forces that trigger 
this branch of research at the INCT-MM. Although the pharmaco-
logical data on P. nigriventer toxins are promising, other studies 
should be performed for better determining the molecular 
targets of these toxins, pharmacokinetics features, clinical 
efficacy, and safety of these drugs. Taking advantage of PET 
techniques, at the INCT - Molecular Medicine, new functional 
in vivo analysis will be done for testing molecular targets, as 
well as pharmacokinetics studies of toxins and natural products 
against neurodegenerative disorders. National Science and 
Technology Institutes are a recent initiative of the Brazilian 
government for funding applied research, allowing the results 
from basic research to be applied to solve health problems. 
Molecular Medicine going through Molecular 
Imaging
Molecular imaging is a new research discipline that visualizes, 
characterizes, and quantifies biologic processes taking place 
at the cellular and molecular levels within humans and other 
living systems. These processes reflect cellular and molecular 
pathways and mechanisms of disease and can be studied in 
their own physiological environment. In contrast to the classi-
cal form of diagnostic imaging in which the recognized findings 
show the end effects of these cellular/molecular changes, the 
molecular imaging relies on the visualization of these changes 
that form the basis of disease in a living subject without any 
level of invasiveness. The molecular imaging uses endogenous 
molecules and exogenous probes to visualize, characterize, and 
measure biological processes in living systems. The interactions 
of the molecules/probes with molecular/cellular targets are 
characterized by two types: a receptor-ligand binding where 
the final product of a specific gene expression in particular 
cells or subcellular compartments is the target or an enzyme 
mediated trapping of labeled substrate. In order to recognize 
targets, molecular imaging applies specific instruments (e.g., 
PET) that enable visualization and quantification in space and 
in real-time of signals from molecular imaging agents. Molecular 
imaging provides measurements of processes at molecular and 
cellular levels and it is a key element of molecular imaging 
data and image analysis, especially for inter- and intra-subject 
comparisons. The molecular imaging acts as complementary 
tool in all activities of our research projects.
PET and microPET technologies
PET
Positron emission tomography (PET) is a non-invasive func-
tional imaging technique with good resolution, high sensitivity, 
and accurate quantification. PET provides quantitative infor-
mation of physiological, biochemical, and pharmacological 
processes in humans and living subjects without disturbing 
the biological system (PET tracers are in picomolar concentra-
tion). PET has been applied as a clinical and medical research 
imaging methodology in the field of oncology, cardiology, and 
neurology.47-49 Furthermore, PET plays an important role in the 
process of drug development and evaluation.50-52
PET requires a tracer that is labeled with a positron emit-
ting radioisotopes and a PET camera for imaging the subject. 
Development of new imaging probes for PET requires a mul-
tidisciplinary approach: target selection, organic synthesis, 
radiolabeling, in vitro and in vivo evaluation, and kinetic 
modeling of the radiolabeled compounds.53 PET is a quantita-
tive imaging tool that measures the regional concentration 
of the probe with a high level of accuracy at the picomolar 
level. Changes in tissue radiotracer concentration with time 
(time-activity curves – TAC, with dynamic acquisitions) and 
standardized uptake value (SUV – with static acquisitions) 
are commonly used parameters to measure PET radiotracer 
concentration in a specific compartment.53,54 The kinetic mod-
eling of PET data may enable the quantification of receptor 
density, enzyme activity, metabolic rate, and perfusion.55
Positron-emitting radionuclides are elements (e.g., 11C, 
13N, 15O) that can replace the stable analogues in drugs and 
biomolecules. Thus, it is possible to synthesize PET probes 
with the same chemical structure as the parent unlabeled 
molecules without altering their biological activity. The 
choice of the PET radionuclide is defined by its physical and 
chemical characteristics availability, the timescale for the 
studied biological process,56 and its physical half-life. If the trac-
ers need to be transported from the radiopharmacy sites to 
the imaging sites, or if significantly long labeling procedure 
is required, it may not be possible to use short lived isotopes 
(e.g., C-11). Tracers labeled with very short half-life (e.g., 
O-15) should be prepared very close to the imaging site.
MicroPET
MicroPET is a miniaturization of clinical PET for small animal 
studies. The first microPET for rats was developed at the 
Crump Institute at UCLA, in collaboration with CTI PET Systems 
(Knoxville, TN).57 Although the prototype had a limited axial 
field-of-view (FOV) and compromised sensitivity,58 it was applied 
to monitor the functional status of the dopaminergic system in a 
rat model of Huntingdon’s disease following the grafting of fetal 
striatum implants.59 PET scans were performed using the post-
synaptic markers (11C) raclopride and (11C) SCH-23390, and the 
investigators were able to assess graft viability non-invasively 
and to correlate dopaminergic function with behavioral assays. 
The latest developments in small animal scanner technology 
represent important and exciting advances in the field of PET, 
arousing great interest. Technological development has now 
reached a great deal of improvement in imaging acquisition and 
resolution. For instance, the microPET recently installed in our 
institution is equipped with a LYSO/LGSO detector, improving 
intrinsic resolution of the system with insignificant dead time 
loss. In addition, it has a great spatial resolution of 1.35 mm 
with Filtered Back Projection (FBP) reconstruction. Likewise, 
data from this scanner is acquired in list mode and, given the 
almost infinitely fine sampling across the detector plates, can 
be reformatted into sinograms of a chosen size. 
PET and microPET applications
Molecular biology
It has now become clear that small animal PET can be em-
ployed in three types of application with a great deal of 
laboratory cost reduction. First, the acquisition of dynamic 
data in microPET provides a complete description of the 
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ligand binding kinetics in a single animal (in contrast to 
ex vivo dissection methods in which each animal can only 
contribute to a single time point). Second, considerably cost 
reduction in the number of animals used to > 50% (e.g., in 
occupancy studies, a minimum of 30 animals is required for 
a saturation curve produced using post-mortem dissection, 
while using microPET the number of animals drops to 12).60 
Finally, whole body biodistribution studies can also be ra-
tionalized using animal PET, as the need to pre-determine 
sacrifice times and target organs for dissection is removed. 
Recently, particular interest has been seen in the imaging of 
gene expression in vivo using PET. The technique was first applied 
by Tjuvajev and co-workers using (124I)-5-iodo-29-fluoro-1-beta-
D-arabinofuranosyl-uracil (124I-FIAU) to image the transfer and 
expression of the herpes virus type 1 thymidine kinase (HSV1-tk) 
reporter gene.61 Then, researchers from the UCLA have reported 
a number of advances in this area.62 The principle of gene im-
aging using PET has now been proven and will be an important 
component of the applications in small animal PET imaging.
Clinical use
Molecular imaging is doubtless a very important diagnostic tool 
in patients with neurological and oncological diseases. The 
ultimate goal is to personalize patient care by characterizing 
specific disease processes in different individuals. By accurately 
characterizing tumor properties or biological processes, mo-
lecular imaging plays an essential role in guiding cancer patient 
management: diagnosing, staging, assessing therapeutic targets, 
monitoring therapy, and evaluating prognoses (17-19). Molecular 
imaging is a very important diagnostic tool in early assessment, 
risk stratification, evaluation, and follow-up of patients with 
neurological diseases (e.g., Alzheimer’s disease, movement 
disorders, seizure disorders, and psychiatric disorders; Figure 2).
Figure 2 Typical example of 18F-FDG PET/CT clinical 
application in Oncology. 
A patient with a history of colon cancer, who underwent a tumor resection 
and chemotherapy, and had a suspected lymph node (LN) involvement in the 
retroperitoneal region on CT scan. 18F-FDG PET/CT scan revealed several 
LNs with high uptake in the retroperitoneal region (arrows) and in the 
mediastinum. A) MIP image; B) Coronal fused image; C) Sagittal fused image; 
D) Axial slice of PET; and E) Axial fused image.
Molecular imaging has great potential to contribute 
to the development of new therapies in oncology and 
neuropsychiatry, as it plays an important role in diagnosis 
and response monitoring. PET radiotracers are now being 
developed as early response markers to assess the impact 
of novel therapies.18F-FDG, an analogous of glucose, is the 
most advanced and used biomarker. However, several other 
probes have been shown promising results for this purpose 
(e.g., 18F-Fluoro-thymidine, 18F-Fluoromisonidazole etc). 
Molecular imaging in oncology could guide patient manage-
ment and drug selection through response monitoring and 
tumor-specific target identification (Figure 3).
Figure 3 An example of 18F-FDG PET/CT application in 
Neurology. A female patient with mild cognitive impairment 
(MCI) who had a PET/CT scan performed. 
The study revealed almost homogeneous 18F-FDG uptake throughout the 
cerebral cortex, basal ganglia, and cerebellum. The parametric analyses 
showed lower Z-score values on temporal lobes and cerebellum (adjusted to 
pons) compared with the normal database for her age. A through D: Axial 
slices of PET; E and G: Parametric analysis; F and H: Z-score analyses.
Drug discovery
The need for innovative therapies has increased due to the 
growing incidence of chronic illnesses, such as cancer, meta-
bolic disorders, and neurological and psychiatric diseases. 
Regardless of a huge variety of drug targets in cancer and 
brain illnesses, the challenges of discovering and developing 
new treatments are appreciable. The high cost of the drug 
development process is unquestionable and successful drug dis-
covery and development is limited to the drug targets and to the 
best molecules towards those targets we choose. Molecular 
imaging is playing an increasingly important role in our efforts 
to direct these challenges. Molecular imaging has potential 
applications throughout the drug discovery and development 
process. Its application can be divided in basically two levels 
of use: the preclinical and clinical settings.
1) Preclinical setting: molecular imaging can help phar-
maceutical companies to validate drug candidates by 
in vivo assessment of accurate titration of therapeutic 
dose and, using a labeled form of the compound, quicker 
characterization of the drug’s pharmacodynamics and 
pharmacokinetics in selected animal models. This 
knowledge will certainly improve data quality, reduce 
number of animals used, and decrease the work-up time 
for new drugs. 
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2) Clinical setting: molecular imaging can also help reduce 
cycle times during drug development in Phase I clinical 
trials (clinical testing strategies can be markedly short-
ened) accelerating dose selection and enabling a focused 
approach to Phase II; in Phases II and III clinical trials, 
molecular imaging biomarkers that recognize therapeu-
tic response and/or disease progression can potentially 
serve as surrogate endpoints for registration and thereby 
speed drug assessment and approval. Thus, molecular 
imaging has been used to stratify patients that will en-
able enrichment of proof of concept clinical studies, 
leading to shorter and potentially more successful trials. 
Such stratification is a key goal of efforts to improve the 
efficiency of drug development and, ultimately, deliver 
the right therapy to the right patient at the right dose. 
Drug development in psychiatry
The process of discovering and bringing a drug to market 
is both time-consuming and money-consuming. In fact, the 
average cost for a new drug to be released is estimated in 
US$ 1 billion, and the entire process usually takes 12-15 years. 
Even then, less than 10% of the drugs that enter a clinical 
trial actually reach the market.57
The use of small-animal PET (saPET) in drug development 
offers many advantages over traditional ex vivo techniques. 
A great benefit in the use of saPET is the fact that the animal 
remains alive, enabling longitudinal studies in which each 
animal can be used as their own control. Because saPET is 
non-invasive, it is feasible to analyze the same animal re-
peated times and in different therapeutic conditions, increas-
ing the results reliability by reducing intersubject variation. 
Another possibility is the use of animals of the same strain, 
which confers a relatively low interanimal variation when 
compared to human subjects.58,63,64
The kinetics of drug absorption, distribution, metabolism, 
and excretion can be estimated with great precision because 
saPET permits the spatial and temporal detection of pico-
molar concentrations of a radiolabeled compound with great 
sensitivity. The brain penetration of a new drug and overall 
pharmacokinetics can be then assumed.59,60,65
The compound’s pharmacodynamic effects can be 
monitored by the usage of different tracers, given that 
many physiological and biochemical parameters can be mea-
sured, such as blood flow, oxygen, and glucose metabolism. 
Furthermore, PET-based receptor occupancy studies may 
elucidate the mechanism of drug action and its ability to 
alter the biological process of disease.63,66,67
One of the greatest saPET applications is elucidating the 
pathophysiology of many diseases. The use of animal models 
of human disease and knock-out or knock-in animals may 
help in understanding the molecular basis and pathogenesis 
of disease, and also may lead to a prediction of the effective 
dose of a compound.65
Small-animal molecular imaging can also be used to ana-
lyze gene expression by using radiolabeld molecular probes 
introduced into target tissue. With the use of mathematical 
models, PET can measure protein synthesis and transport, 
allowing the analysis of biological changes deriving from 
gene modification.66
In collaboration with pharmaceutical companies this great 
potential of saPET in drug discovery will be explored. INCT-
MM has a LabPET 4 PET Scanner system that will be used in 
the development of new tracers, and for this purpose it will 
be installed in a facility adjacent to the cyclotron located 
at the main Campus of UFMG. 
Discussion
Molecular imaging represents a complementary tool for Molecular 
Medicine providing a key analysis pathway between the mo-
lecular mechanisms involved in the pathophysiology of disease 
and therapies targeted to those, resulting in better, faster, 
and cost-effective decision making. Molecular imaging helps 
prompt drug development towards the best drug candidate, 
therefore, enhancing safe drug delivery to people who need 
them. Previously, we have developed genetic, psychological and 
animal models to support the research in psychiatry and basic 
science. Our infrastructure allowed us to create and maintain a 
post-graduation program in Molecular Medicine, where we are 
promoting the necessary training of specialized human resources 
in the area, particularly in molecular imaging.
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